WOOF Stock Analysis: Petco Health Wellness | NASDAQ
Specialty Retail | NASDAQ, USA | Market Cap: 788m USD | 12M Return: -28.7% | US71601V1052 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.16M
Qual. Beats: 0
Rev. Trend: -84.4%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) is a U.S.-headquartered pet specialty retailer that operates across the United States, Mexico, Puerto Rico, and Chile. Founded in 1965 and based in San Diego, California, the company offers a mix of products and services including pet care supplies, companion animals, veterinary care, grooming, and training, distributed through physical retail locations and its petco.com website and mobile app. Petco sells under several house brands, including WholeHearted, Reddy, So Phresh, and Well & Good, and positions itself around the whole pet concept addressing pets physical, mental, and social well-being. The company went public in January 2021 and is classified within the Consumer Discretionary sector under Other Specialty Retail.
The pet specialty retail industry combines merchandise sales with higher-margin services such as veterinary care and grooming, and has increasingly shifted toward an omnichannel model where in-store, e-commerce, and mobile app experiences are integrated. Petcos main competition includes large-format pet chains and online-focused retailers, and the broader U.S. pet category is supported by relatively resilient consumer spending on pets, even during broader retail downturns.
- Veterinary services segment revenue accelerates with new clinic openings
- Comparable sales decline as discretionary pet spending softens
- Private label brands like WholeHearted boost gross margins
| Net Income: 5.58m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 3.65 > 1.0 |
| NWC/Revenue: -2.84% < 20% (prev -2.68%; Δ -0.16% < -1%) |
| CFO/TA 0.07 > 3% & CFO 360.2m > Net Income 5.58m |
| Net Debt (3.93b) to EBITDA (330.8m): 11.87 < 3 |
| Current Ratio: 0.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (283.7m) vs 12m ago 2.21% < -2% |
| Gross Margin: 38.72% > 18% (prev 36.43%; Δ 2.29% > 0.5%) |
| Asset Turnover: 116.9% > 50% (prev 118.7%; Δ -1.85% > 0%) |
| Interest Coverage Ratio: 1.04 > 6 (EBIT TTM 135.1m / Interest Expense TTM 130.5m) |
| A: -0.03 (Total Current Assets 960.8m - Total Current Liabilities 1.13b) / Total Assets 5.08b |
| B: -0.23 (Retained Earnings -1.16b / Total Assets 5.08b) |
| C: 0.03 (EBIT TTM 135.1m / Avg Total Assets 5.10b) |
| D: 0.29 (Book Value of Equity 1.16b / Total Liabilities 3.93b) |
| Altman-Z'' = -0.47 = B |
| DSRI: 1.04 (Receivables 36.9m/36.1m, Revenue 5.96b/6.08b) |
| GMI: 0.94 (GM 36.43% / 38.72%) |
| AQI: 1.01 (AQ_t 0.44 / AQ_t-1 0.43) |
| SGI: 0.98 (Revenue 5.96b / 6.08b) |
| TATA: -0.07 (NI 5.58m - CFO 360.2m) / TA 5.08b) |
| Beneish M = -3.06 (Cap -4..+1) = AA |
As of September 02, 2026, the stock is trading at USD 2.58 with a total of 1,564,654 shares traded. Over the past week, the price has changed by -6.52%, over one month by -11.34%, over three months by -15.69% and over the past year by -28.73%.
Current recommended Stop Loss: 2.40 (which is 7% or 1.6 ATR below the current price).
Petco Health Wellness has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold WOOF.
- StrongBuy: 0
- Buy: 2
- Hold: 8
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 3.5 | 37.2% |
P/E Trailing = 138.0
P/E Forward = 13.089
P/S = 0.1321
P/B = 0.7119
Revenue TTM = 5.96b USD
EBIT TTM = 135.1m USD
EBITDA TTM = 330.8m USD
Long Term Debt = 1.46b USD (from longTermDebt, last quarter)
Short Term Debt = 325.6m USD (from shortTermDebt, last quarter)
Debt = 4.09b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.31b
Net Debt = 3.93b USD (calculated: Debt 4.09b - CCE 166.8m)
Enterprise Value = 4.71b USD (788.2m + Debt 4.09b - CCE 166.8m)
Interest Coverage Ratio = 1.04 (Ebit TTM 135.1m / Interest Expense TTM 130.5m)
EV/FCF = 20.31x (Enterprise Value 4.71b / FCF TTM 232.1m)
FCF Yield = 4.92% (FCF TTM 232.1m / Enterprise Value 4.71b)
FCF Margin = 3.89% (FCF TTM 232.1m / Revenue TTM 5.96b)
Net Margin = 0.09% (Net Income TTM 5.58m / Revenue TTM 5.96b)
Gross Margin = 38.72% ((Revenue TTM 5.96b - Cost of Revenue TTM 3.66b) / Revenue TTM)
Gross Margin QoQ = 38.38% (prev 38.33%)
Tobins Q-Ratio = 0.93 (Enterprise Value 4.71b / Total Assets 5.08b)
Interest Expense / Debt = 3.19% (Interest Expense 130.5m / Debt 4.09b)
Taxrate = 35.70% (3.10m / 8.68m)
NOPAT = 86.9m (EBIT 135.1m * (1 - 35.70%))
Current Ratio = 0.85 (Total Current Assets 960.8m / Total Current Liabilities 1.13b)
Debt / Equity = 3.54 (Debt 4.09b / totalStockholderEquity, last quarter 1.16b)
Debt / EBITDA = 11.87 (Net Debt 3.93b / EBITDA 330.8m)
Debt / FCF = 16.92 (Net Debt 3.93b / FCF TTM 232.1m)
Total Stockholder Equity = 1.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.11% (Net Income 5.58m / Total Assets 5.08b)
RoE = 0.48% (Net Income TTM 5.58m / Total Stockholder Equity 1.15b)
RoCE = 5.16% (EBIT 135.1m / Capital Employed (Equity 1.15b + L.T.Debt 1.46b))
RoIC = 2.11% (NOPAT 86.9m / Invested Capital 4.11b)
WACC = 3.33% (E(788.2m)/V(4.88b) * Re(10.0%) + D(4.09b)/V(4.88b) * Rd(3.19%) * (1-Tc(0.36)))
Discount Rate = 10.0% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.62 | Cagr: 2.46%
[DCF] Terminal Value 77.97% ; FCFF base≈158.0m ; Y1≈181.1m ; Y5≈266.5m
[DCF] Fair Price = 0.35 (EV 4.01b - Net Debt 3.93b = Equity 85.6m / Shares 247.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -84.43 | Revenue CAGR: -1.65% | SUE: 1.13 | # QB: 1
EPS current Quarter (2026-07-31): EPS=0.07 | Chg30d=+0.00% | Revisions=-17% | Analysts=8
EPS next Quarter (2026-10-31): EPS=0.06 | Chg30d=+0.00% | Revisions=-17% | Analysts=8
EPS current Year (2027-01-31): EPS=0.22 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+16.9% | GrowthRev=+0.6%
EPS next Year (2028-01-31): EPS=0.28 | Chg30d=+0.00% | Revisions=-12% | GrowthEPS=+24.8% | GrowthRev=+1.5%
[Analyst] Revisions Ratio: -17% (up=6, down=9)